Stuart Newman
Ophthalmology · Roswell, GANPI 1255338653
Payments from drug & device makers
Across 102 payments — averaging $32.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$544
- Coopervision Inc.$514
- Novartis$442
- AbbVie$300
- Carl Zeiss Meditec, Inc.$208
- Shire North American Group Inc$155
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,83585%
- Education$50015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 11 | $544 |
| Coopervision Inc. | 3 | $514 |
| Novartis | 17 | $442 |
| AbbVie(2 entities) | 15 | $300 |
| Carl Zeiss Meditec, Inc. | 2 | $208 |
| Shire North American Group Inc | 4 | $155 |
| Kala Pharmaceuticals, Inc. | 8 | $152 |
| Glaukos Corporation | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 6 | $116 |
| Quidel Corporation | 1 | $95 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $83 |
| Oyster Point Pharma, Inc. | 4 | $80 |
| Biotissue Holdings Inc. | 4 | $75 |
| Thea Pharma Inc. | 3 | $73 |
| Akorn, Inc. | 3 | $71 |
| Eyevance Pharmaceuticals LLC | 3 | $58 |
| Aerie Pharmaceuticals, Inc. | 3 | $54 |
| Akorn Operating Company LLC | 2 | $52 |
| Alcon | 2 | $41 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $35 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Sight Sciences, Inc. | 1 | $21 |
| Dompe US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,335 in reported general payments places this provider in the 60th percentile of 481 ophthalmology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 14 | $17,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $300 | $17,83114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Roswell
- Larry HeitRoswell$25K
- Dennis MarcusAugusta$9.2M
- Robert StoltzMarietta$3.9M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Lakshmana KooragayalaMarietta$1.4M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
- Gagan SawhneyAtlanta$874K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.